Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes
Phase of Trial: Phase III
Latest Information Update: 04 Apr 2017
At a glance
- Drugs Insulin aspart (Primary) ; Insulin; Insulin detemir; Insulin glargine; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms Onset 3
- Sponsors Novo Nordisk
- 07 Jun 2017 Biomarkers information updated
- 10 Jan 2017 According to a Novo Nordisk media release, the European Commission has granted marketing authorization for Fiasp for the treatment of diabetes in adults based on data from this and other three trials (231999, 226655, 238002 trials from ONSET programme).
- 06 Jan 2017 According to a Novo Nordisk media release, Fiasp has received marketing authorization from Health Canada.